X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (912) 912
pyrrolidinones - pharmacology (688) 688
male (684) 684
animals (628) 628
index medicus (570) 570
female (445) 445
adult (321) 321
pharmacology & pharmacy (316) 316
rats (314) 314
raltegravir potassium (304) 304
middle aged (267) 267
pyrrolidinones - therapeutic use (263) 263
estrenes - pharmacology (228) 228
hiv infections - drug therapy (218) 218
pyrrolidinones - administration & dosage (181) 181
pyrrolidinones - blood (175) 175
infectious diseases (173) 173
mice (160) 160
raltegravir (159) 159
dose-response relationship, drug (156) 156
phosphodiesterase inhibitors - pharmacology (155) 155
pyrrolidinones - pharmacokinetics (153) 153
rolipram (139) 139
immunology (134) 134
type c phospholipases - antagonists & inhibitors (122) 122
pyrrolidinones - chemistry (118) 118
hiv (116) 116
pyrrolidinones - adverse effects (111) 111
calcium - metabolism (108) 108
pharmacokinetics (104) 104
rats, sprague-dawley (104) 104
time factors (103) 103
aged (100) 100
enzyme inhibitors - pharmacology (99) 99
hiv infections - virology (96) 96
treatment outcome (93) 93
microbiology (92) 92
analysis (89) 89
cells, cultured (89) 89
biochemistry & molecular biology (88) 88
in vitro techniques (87) 87
research (85) 85
physiology (82) 82
antiviral agents (81) 81
activation (79) 79
cell biology (79) 79
cotinine - blood (78) 78
viral load (78) 78
anti-hiv agents - therapeutic use (77) 77
hiv-1 - drug effects (76) 76
neurosciences (75) 75
rats, wistar (75) 75
young adult (72) 72
drug therapy (70) 70
virology (70) 70
rna, viral - blood (69) 69
type c phospholipases - metabolism (69) 69
cd4 lymphocyte count (67) 67
expression (67) 67
pyrrolidinones (67) 67
research article (67) 67
antiretroviral therapy (65) 65
drug therapy, combination (65) 65
blood pressure - drug effects (64) 64
pyrrolidinones - metabolism (64) 64
drug interactions (63) 63
adolescent (62) 62
dogs (60) 60
safety (59) 59
cells (58) 58
hiv infection (58) 58
kinetics (57) 57
pyrrolidinones - analysis (55) 55
hiv integrase inhibitors - therapeutic use (54) 54
hiv-1 - genetics (54) 54
signal transduction - drug effects (54) 54
article (53) 53
anti-hiv agents - administration & dosage (52) 52
efficacy (52) 52
health aspects (52) 52
dosage and administration (51) 51
hiv infections - blood (51) 51
calcium (50) 50
rabbits (50) 50
toxicology (50) 50
aids/hiv (48) 48
double-blind (48) 48
therapy (48) 48
double-blind method (47) 47
infection (47) 47
care and treatment (46) 46
cell line (46) 46
drugs (46) 46
smoking (46) 46
hiv-1 (45) 45
medicine (45) 45
plasma (45) 45
oncology (44) 44
piracetam - pharmacology (44) 44
human immunodeficiency virus--hiv (43) 43
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1360) 1360
Russian (30) 30
Japanese (17) 17
German (13) 13
Italian (9) 9
French (7) 7
Portuguese (4) 4
Chinese (3) 3
Polish (3) 3
Spanish (2) 2
Croatian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


AIDS, ISSN 0269-9370, 11/2012, Volume 26, Issue 18, pp. 2315 - 2326
Background: Switching from boosted protease inhibitors (PI/r) to raltegravir (RAL) results in a better plasma lipid profile than continuing PI/r. Whether this... 
switching | protease inhibitors | raltegravir | cardiovascular biomarkers | INTIMA-MEDIA THICKNESS | ABACAVIR | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | MARKERS | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | ENDOTHELIAL FUNCTION | TRIAL | VIROLOGY | EFAVIRENZ | TENOFOVIR/EMTRICITABINE | MOLECULAR-MECHANISMS | Anti-HIV Agents - pharmacology | Follow-Up Studies | P-Selectin - metabolism | Humans | Middle Aged | Tumor Necrosis Factor-alpha - blood | Interleukin-10 - blood | Male | HIV Protease Inhibitors - pharmacology | C-Reactive Protein - metabolism | Interleukin-6 - blood | Lipids - blood | Pyrrolidinones - pharmacology | Osteoprotegerin - blood | Adult | Female | Ritonavir - pharmacology | Raltegravir Potassium | Atherosclerosis - drug therapy | Fasting | Drug Administration Schedule | Atherosclerosis - physiopathology | E-Selectin - metabolism | Biomarkers - blood | Chemokine CCL2 - blood | Vascular Cell Adhesion Molecule-1 - blood | Atherosclerosis - blood | HIV Infections - drug therapy | HIV Infections - physiopathology | HIV Infections - metabolism | Drugs | C-reactive protein | biomarkers | Clinical trials | Lipids | Proteinase inhibitors | Triglycerides | intercellular adhesion molecule 1 | Insulin | Cholesterol | Adiponectin | Osteoprotegerin | Interleukin 6 | E-selectin | Lipoproteins | Arteriosclerosis | Interleukin 10 | vascular cell adhesion molecule 1 | Monocyte chemoattractant protein 1 | P-selectin | Tumor necrosis factor- alpha
Journal Article
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 03/2012, Volume 59, Issue 3, pp. 229 - 235
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 06/2017, Volume 255, pp. 54 - 61
Journal Article
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 01/2018, Volume 84, Issue 1, pp. 112 - 121
Aims This phase 1, open‐label, crossover study sought to evaluate drug–drug interactions between tivantinib and cytochrome P450 (CYP) substrates and tivantinib... 
pharmacokinetics | cancer | P‐glycoprotein | cytochrome P450 | tivantinib | drug interaction | P-glycoprotein | ADVANCED HEPATOCELLULAR-CARCINOMA | TARGETING MET | CYTOTOXIC ACTIVITY | COOPERSTOWN 5+1 COCKTAIL | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | METABOLISM | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | MET INHIBITION | PHASE-I | Neoplasms - metabolism | Quinolines - blood | Chromatography, High Pressure Liquid - methods | Humans | Middle Aged | Omeprazole - blood | Cytochrome P-450 Enzyme System - metabolism | Male | Antineoplastic Agents - therapeutic use | Quinolines - pharmacology | Warfarin - pharmacology | Drug Interactions | Neoplasms - blood | Pyrrolidinones - pharmacology | Aged, 80 and over | Caffeine - pharmacology | Adult | Female | Omeprazole - pharmacology | Antineoplastic Agents - pharmacology | Tandem Mass Spectrometry - methods | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Caffeine - blood | Pyrrolidinones - therapeutic use | Pyrrolidinones - blood | ATP Binding Cassette Transporter, Subfamily B - metabolism | Neoplasms - drug therapy | Cross-Over Studies | Drug Therapy, Combination - methods | Midazolam - blood | Warfarin - blood | Antineoplastic Agents - blood | Aged | Quinolines - therapeutic use | Midazolam - pharmacology | Medical research | Care and treatment | Warfarin | Digoxin | Drug interactions | Cytochrome P-450 | Omeprazole | Complications and side effects | Analysis | Medicine, Experimental | Dosage and administration | Tumors | Caffeine
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 11/2013, Volume 64, Issue 3, pp. 279 - 283
Journal Article
Journal Article
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 10/2006, Volume 116, Issue 10, pp. 2739 - 2747
In this study we investigated why bloodstream forms of Trypanosoma brucei gambiense cross human brain microvascular endothelial cells (BMECs), a human... 
Leucine - pharmacology | Blood-Brain Barrier - cytology | Calcium - metabolism | Calcium Signaling - physiology | Humans | Pyrrolidinones - pharmacokinetics | Cell Communication - physiology | Culture Media, Conditioned - pharmacology | Trypanosoma brucei brucei - enzymology | Vinyl Compounds - pharmacology | Cell Movement - physiology | Endothelial Cells - parasitology | Cysteine Endopeptidases - metabolism | Protozoan Proteins - metabolism | Trypanosoma brucei rhodesiense - metabolism | Egtazic Acid - analogs & derivatives | Estrenes - pharmacokinetics | Blood-Brain Barrier - parasitology | Trypanosoma - enzymology | Leucine - analogs & derivatives | Cathepsins - antagonists & inhibitors | Trypanosoma brucei brucei - metabolism | Endothelial Cells - metabolism | Trypanosoma brucei gambiense - metabolism | Dipeptides - pharmacology | Cells, Cultured | Blood-Brain Barrier - metabolism | Naphthalenes - pharmacology | Cell Movement - drug effects | Animals | Egtazic Acid - pharmacology | Trypanosoma - metabolism | Calcium Signaling - drug effects | Cathepsins - metabolism | Endothelial Cells - cytology | Cysteine Proteinase Inhibitors - pharmacology | Cell Communication - drug effects | Trypanosoma brucei gambiense - enzymology | Trypanosoma brucei rhodesiense - enzymology | Cathepsins | Research | Trypanosoma brucei | Analysis
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 4/2013, Volume 207, Issue 8, pp. 1226 - 1234
Background. Effective antiretroviral therapy (ART) dramatically reduces human immunodeficiency virus (HIV) transmission. However, isolated shedding of HIV type... 
HIV/AIDS | Antiretrovirals | HIV | RNA | Semen | Men | Viruses | Viral load | Blood | HIV 1 | Blood plasma | semen | transmission | viral load | antiretroviral therapy | INFECTIOUS DISEASES | RALTEGRAVIR | BLOOD-PLASMA | MICROBIOLOGY | TREATED PATIENTS | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | SEMINAL PLASMA SAMPLES | PROTEASE INHIBITORS | MALE GENITAL-TRACT | HIV-1-INFECTED MEN | INFECTED PATIENTS | HIV-1 - pathogenicity | Prospective Studies | Triazoles - blood | Cyclohexanes - pharmacology | Humans | Molecular Sequence Data | Male | RNA, Viral - blood | Virus Shedding | Case-Control Studies | Viral Load | Incidence | Cyclohexanes - therapeutic use | RNA, Viral - genetics | Time Factors | Base Sequence | Pyrrolidinones - pharmacology | HIV Infections - transmission | Anti-Retroviral Agents - blood | Semen - virology | Raltegravir Potassium | Triazoles - therapeutic use | Amino Acid Sequence | Anti-Retroviral Agents - therapeutic use | Sexual Behavior | HIV Infections - virology | Anti-Retroviral Agents - pharmacology | Pyrrolidinones - therapeutic use | Pyrrolidinones - blood | Treatment Outcome | HIV-1 - genetics | Cyclohexanes - blood | Triazoles - pharmacology | Sequence Analysis, RNA | Viremia - virology | HIV Infections - drug therapy | Antiviral agents | Development and progression | Genetic aspects | Dosage and administration | Research | HIV infection
Journal Article
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 2009, Volume 49, Issue 2, pp. 451 - 458
Journal Article
AIDS, ISSN 0269-9370, 01/2012, Volume 26, Issue 2, pp. 167 - 174
Journal Article